Last reviewed · How we verify
Blinatumomab plus Reduced-dose Chemotherapy
Blinatumomab targets CD19 and CD3 on T cells, leading to T cell activation and killing of B cell malignancies.
Blinatumomab targets CD19 and CD3 on T cells, leading to T cell activation and killing of B cell malignancies. Used for Acute Lymphoblastic Leukemia (ALL).
At a glance
| Generic name | Blinatumomab plus Reduced-dose Chemotherapy |
|---|---|
| Sponsor | Xianmin Song, MD |
| Drug class | Bispecific monoclonal antibody |
| Target | CD19 and CD3 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Blinatumomab is a bispecific monoclonal antibody that binds to CD19 on B cells and CD3 on T cells, leading to T cell activation and killing of B cell malignancies.
Approved indications
- Acute Lymphoblastic Leukemia (ALL)
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Leukopenia
- Infections
- Fatigue
- Nausea
- Diarrhea
- Vomiting
- Headache
Key clinical trials
- Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL (NA)
- Treatment of Older Patients With B-precursor ALL With Sequential Dose Reduced Chemotherapy and Blinatumomab (PHASE2)
- Newly-diagnosed Pediatric Ph-positive B-ALL Protocol (PHASE3)
- Impact of Low-intensity Chemotherapy Combined With Short-course Blinatumomab on Allo-HSCT in Adults With Ph- B-ALL (PHASE2)
- Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (PHASE2)
- Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT (PHASE2)
- Blinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL (PHASE2)
- Reduced-Dose Chemo Followed by 14 Days of Blinatumomab for Newly Diagnosed Adult B-ALL Patients: a Multicenter Study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: